U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry RACEMIC
Molecular Formula C18H29N3O5
Molecular Weight 367.4407
Optical Activity ( + / - )
Defined Stereocenters 0 / 1
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of BAMBUTEROL

SMILES

CC(C)(C)NCC(c1cc(cc(c1)OC(=O)N(C)C)OC(=O)N(C)C)O

InChI

InChIKey=ANZXOIAKUNOVQU-UHFFFAOYSA-N
InChI=1S/C18H29N3O5/c1-18(2,3)19-11-15(22)12-8-13(25-16(23)20(4)5)10-14(9-12)26-17(24)21(6)7/h8-10,15,19,22H,11H2,1-7H3

HIDE SMILES / InChI
Molecular Formula C18H29N3O5
Molecular Weight 367.4407
Charge 0
Count
Stereochemistry RACEMIC
Additional Stereochemistry No
Defined Stereocenters 0 / 1
E/Z Centers 0
Optical Activity ( + / - )

Description
Curator's Comment:: Description was created based on several sources, including https://www.medicines.org.uk/emc/medicine/9574 | http://www.meppo.com/pdf/drugs/2596-BAMBEC-ORAL-SOLUTION-1427211370.pdf | https://www.ncbi.nlm.nih.gov/pubmed/2906603

Bambuterol is an active precursor of the selective beta2-adrenergic agonist terbutaline. Bambuterol is the bis-N,N-dimethyl-carbamate of terbutaline. Bambuterol is a remarkably selective and potent inhibitor of cholinesterase. BAMBEC (Bambuterol hydrochloride) oral solution or tablets are indicated for the management of asthma, bronchospasm and/or reversible airways obstruction.

CNS Activity

CNS Non-penetrant
1062
Curator's Comment:: Bambuterol distribution to CNS is negligible, however chronic, but not acute, treatment with bambuterol relieves allodynia in a murine model of neuropathy.

Originator

AstraZeneca
119
Curator's Comment:: # AB Draco (Subsidiary of AB Astra, now AstraZeneca)

Approval Year

Unknown
109281
Targets

Targets

Primary TargetPharmacologyConditionPotency
Agonist
2470
Inhibitor
7728
 17.0 nM [IC50]
Conditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Primary
Approved
8043
BAMBEC

Approved Use

BAMBEC (Bambuterol hydrochloride) oral solution or tablets are indicated for the management of asthma, bronchospasm and/or reversible airways obstruction.
Primary
Approved
8043
BAMBEC

Approved Use

BAMBEC (Bambuterol hydrochloride) oral solution or tablets are indicated for the management of asthma, bronchospasm and/or reversible airways obstruction.
PubMed

PubMed

TitleDatePubMed
Therapeutic equivalence between bambuterol, 10 mg once daily, and terbutaline controlled release, 5 mg twice daily, in mild to moderate asthma.
1993 Nov
Risk of non-fatal cardiac failure and ischaemic heart disease with long acting beta 2 agonists.
1998 Jul
Cholinesterases: new roles in brain function and in Alzheimer's disease.
2003 Apr
Patents

Patents

JP2006504666A
8
JP2007500151A
15

Sample Use Guides

In Vivo Use Guide
BAMBEC (Bambuterol hydrochloride) Tablets 10 mg. The recommended starting doses are 10 mg–20 mg. The 10 mg dose may be increased to 20 mg if necessary after 1–2 weeks, depending on the clinical effect. In patients who have previously tolerated beta2-agonists well, the recommended starting dose, as well as maintenance dose, is 20 mg. BAMBEC (Bambuterol hydrochloride) oral solution 1mg/ml. The recommended initial dose is 10mg (10ml). The dose may be increased to 20mg (20ml) after 1-2 weeks, depending on the clinical effect. In patients who previously have tolerated oral beta2-agonists well, the recommended initial dose is 20mg (20ml).
Route of Administration: Oral
In Vitro Use Guide
Unknown
Substance Class Chemical
Created
by admin
on Sat Jun 26 16:17:59 UTC 2021
Edited
by admin
on Sat Jun 26 16:17:59 UTC 2021
Record UNII
Y1850G1OVC
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
BAMBUTEROL
INN   MI   WHO-DD  
INN  
Official Name English
BAMBUTEROL [INN]
Common Name English
BAMBUTEROL [WHO-DD]
Common Name English
(+/-)-5-(2-(TERT-BUTYLAMINO)-1-HYDROXYETHYL)-M-PHENYLENE BIS(DIMETHYLCARBAMATE)
Systematic Name English
BAMBUTEROL [MI]
Common Name English
Classification Tree Code System Code
WHO-VATC QR03CC12
Created by admin on Sat Jun 26 16:18:00 UTC 2021 , Edited by admin on Sat Jun 26 16:18:00 UTC 2021
WHO-ATC R03CC12
Created by admin on Sat Jun 26 16:18:00 UTC 2021 , Edited by admin on Sat Jun 26 16:18:00 UTC 2021
NCI_THESAURUS C48149
Created by admin on Sat Jun 26 16:18:00 UTC 2021 , Edited by admin on Sat Jun 26 16:18:00 UTC 2021
Code System Code Type Description
CAS
81732-65-2
Created by admin on Sat Jun 26 16:18:00 UTC 2021 , Edited by admin on Sat Jun 26 16:18:00 UTC 2021
PRIMARY
WIKIPEDIA
BAMBUTEROL
Created by admin on Sat Jun 26 16:18:00 UTC 2021 , Edited by admin on Sat Jun 26 16:18:00 UTC 2021
PRIMARY
EPA CompTox
81732-65-2
Created by admin on Sat Jun 26 16:18:00 UTC 2021 , Edited by admin on Sat Jun 26 16:18:00 UTC 2021
PRIMARY
PUBCHEM
54766
Created by admin on Sat Jun 26 16:18:00 UTC 2021 , Edited by admin on Sat Jun 26 16:18:00 UTC 2021
PRIMARY
FDA UNII
Y1850G1OVC
Created by admin on Sat Jun 26 16:18:00 UTC 2021 , Edited by admin on Sat Jun 26 16:18:00 UTC 2021
PRIMARY
MERCK INDEX
M2216
Created by admin on Sat Jun 26 16:18:00 UTC 2021 , Edited by admin on Sat Jun 26 16:18:00 UTC 2021
PRIMARY Merck Index
ChEMBL
CHEMBL521589
Created by admin on Sat Jun 26 16:18:00 UTC 2021 , Edited by admin on Sat Jun 26 16:18:00 UTC 2021
PRIMARY
DRUG CENTRAL
285
Created by admin on Sat Jun 26 16:18:00 UTC 2021 , Edited by admin on Sat Jun 26 16:18:00 UTC 2021
PRIMARY
RXCUI
18751
Created by admin on Sat Jun 26 16:18:00 UTC 2021 , Edited by admin on Sat Jun 26 16:18:00 UTC 2021
PRIMARY RxNorm
IUPHAR
6601
Created by admin on Sat Jun 26 16:18:00 UTC 2021 , Edited by admin on Sat Jun 26 16:18:00 UTC 2021
PRIMARY
EVMPD
SUB06095MIG
Created by admin on Sat Jun 26 16:18:00 UTC 2021 , Edited by admin on Sat Jun 26 16:18:00 UTC 2021
PRIMARY
INN
5304
Created by admin on Sat Jun 26 16:18:00 UTC 2021 , Edited by admin on Sat Jun 26 16:18:00 UTC 2021
PRIMARY
DRUG BANK
DB01408
Created by admin on Sat Jun 26 16:18:00 UTC 2021 , Edited by admin on Sat Jun 26 16:18:00 UTC 2021
PRIMARY
MESH
C047766
Created by admin on Sat Jun 26 16:18:00 UTC 2021 , Edited by admin on Sat Jun 26 16:18:00 UTC 2021
PRIMARY
NCI_THESAURUS
C81692
Created by admin on Sat Jun 26 16:18:00 UTC 2021 , Edited by admin on Sat Jun 26 16:18:00 UTC 2021
PRIMARY
Related Record Type Details
Structure of BAMBUTEROL, (S)-
ENANTIOMER -> RACEMATE
Structure of BAMBUTEROL, (R)-
ENANTIOMER -> RACEMATE
BETA-2 ADRENERGIC RECEPTOR
TARGET -> AGONIST
SHORT-ACTING
Structure of BAMBUTEROL HYDROCHLORIDE
SALT/SOLVATE -> PARENT
Related Record Type Details
Structure of BAMBUTEROL
ACTIVE MOIETY
NIH
NCATS
PRIVACY ACT
ACCESSIBILITY
DISCLAIMER
HHS VULNERABILITY DISCLOSURE
For language access assistance, contact the NCATS Public Information Officer
National Center for Advancing Translational Sciences (NCATS),
6701 Democracy Boulevard, Bethesda MD 20892-4874 • 301-594-8966